絞り込み

16546

広告

1033件中 181件~200件表示    検索結果をPubMedで見る PubMedで見る

Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer.

Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer.

A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations.

Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients.

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.

EGFR-mediated interleukin enhancer-binding factor 3 contributes to formation and survival of cancer stem-like tumorspheres as a therapeutic target against EGFR-positive non-small cell lung cancer.

Treatment After First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small-Cell Lung Cancer.

Improvement of erosive pustular dermatosis of the scalp following discontinuation of chemotherapy with afatinib.

[A case report of afatinib-induced interstitial lung disease].

Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma.

MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib.

[Analysis of Time-to-onset of Interstitial Lung Disease after the Administration of Small Molecule Molecularly-targeted Drugs].

Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors.

Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers.

Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry.

Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies.

Investigation of the binding characteristics between ligands and epidermal growth factor receptor by cell membrane chromatography.

Activity and safety of afatinib in a window pre-operative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN).

Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2.

  1. 6
  2. 7
  3. 8
  4. 9
  5. 10
  6. 11
  7. 12
  8. 13
  9. 14
  10. 15
Sort by
※並べ替えは表示に時間がかかります